CHICAGO--(BUSINESS WIRE)--PRESS RELEASE--Cresco Labs, Inc., one of the largest vertically integrated multistate cannabis operators in the United States, has released its financial results for the third quarter and nine months ended Sept. 30, 2018. All financial information presented in this release is in U.S. dollars, unless otherwise noted.
Subsequent to the end of third quarter 2018, the company completed a business combination with Randsburg International Gold Corp. upon which its subordinate voting shares were approved for listing on the Canadian Securities Exchange (CSE) under the symbol “CL.” Cresco’s shares began trading on the CSE on Monday, Dec. 3, 2018. The company is in the process of receiving approval by FINRA to list on the OTC market in the U.S. and is currently trading under the symbol “CRLBF.” Concurrent with its public listing on the CSE, Cresco launched its new investors website at investors.crescolabs.com.
“As one of the early cannabis companies to establish a national geographic footprint with substantial population reach and production capacity, Cresco is leading the way in normalizing and professionalizing our industry,” said Charles Bachtell, co-founder and CEO of Cresco Labs. “As a multi-state operator, we have repeatedly proven our ability to get access to markets, get operational, get product to market and get disproportionate market share. Early on in our formation, we realized that cannabis is a natural fit within consumer-packaged goods–an industry that requires consistency, reliability and availability. We therefore developed a unique and sophisticated ‘house of brands’ that addresses each major market segment and covers all price points. In essence, we developed a disciplined business blueprint that enables our rapid entry into regulated markets, where operator obligations are stringent, where our products can be accessible to customers, and where we can capture leading market share right from the start.
“Through our differentiated business approach, we have already proven that our capital starts working immediately to the benefit of our shareholders, regulators, legislators and consumers,” Bachtell continued. “Now, with increased access to the capital markets through our public listing, we can take our expansion strategy to the next level. We believe that Cresco has built the foundation needed to generate strong growth and attractive shareholder returns in the years ahead.”
Financial Results for the Third Quarter Ended Sept. 30, 2018
Revenue for the third quarter of 2018 was $12.2 million, an increase of 335 percent compared to revenue of $2.8 million for the third quarter of 2017. The increase in revenue was driven by market expansion and gains in market share in the states where the company operates. Third quarter revenue increased 51 percent compared to $8.1 million for the second quarter of 2018.
On a pro forma basis, revenue for the third quarter was $16.3 million compared to $11.8 million for the second quarter of 2018, an increase of 39 percent.
Third quarter gross profit, before the gain from biological assets, was $5.4 million, or 45 percent of revenues, compared to less than $0.1 million, or 1 percent of revenues, for the third quarter of 2017 and $3.5 million, or 43 percent of revenues, for the second quarter of 2018.
Net income for the third quarter was $3.9 million, compared to net loss of $0.2 million for the prior-year period. Net income nearly doubled from $2.0 million for the second quarter of 2018.
Adjusted EBITDA for the third quarter was $5.3 million, compared to less than $0.1 million for the third quarter of 2017 and $2.1 million for the second quarter of 2018. Pro forma adjusted EBITDA was $5.9 million for the third quarter and $2.7 million for the second quarter of 2018.
Balance Sheet and Liquidity
As of Sept. 30, 2018, the company had total assets of $149.5 million, including cash and cash equivalents of $93.9 million, which does not reflect the full amount of proceeds from financing activities completed subsequent to the end of the quarter. Long-term liabilities totaled $2.0 million. At Sept. 30, 2018, the company had a working capital position of $105.3 million.
Subsequent to the end of the third quarter of 2018, the company increased its liquidity through additional capital raises:
- In October, the company closed a $100 million Series F private funding raise, the second largest private funding round in U.S. cannabis history at that time. A portion of the round was funded in late September and a substantial amount was funded during the fourth quarter of 2018.
- In November, in connection with its business combination with Randsburg International Gold Corp., Cresco raised gross proceeds of $85 million comprised primarily of funds from institutional investors, and on Dec. 3, 2018, the company began trading on CSE under the ticker symbol "CL."
- Nevada: Launched Mindy’s Edibles and Mindy’s Kitchen with expansive distribution.
- Ohio: While the program has experienced slight delays, Cresco’s first harvest in Yellow Springs will take place in the fourth quarter and the Wintersville dispensary will be the first dispensary in the state to receive operational approval during the same period.
- Pennsylvania: Developing expansion plan of 75,000 square feet in Brookville cultivation facility including a new greenhouse that will increase capacity by four times.
- California: First harvest from seven-acre production site located along the central coast.
- Illinois: Doubled cultivation capacity and quadrupled production and manufacturing capacity across three facilities; added a sophisticated edibles kitchen.
- Illinois: Acquired 100 percent of the membership interests of FloraMedex, LLC and an affiliated real estate entity, including an operational medical marijuana dispensary in Elmwood Park.
- Illinois: Market growth in the state has been driven by an increasing number of registered patients and the recently passed Illinois Alternatives to Opioids Act which, when fully implemented during the first quarter of 2019, is expected to vastly expand the population of patients that can access medical cannabis in place of pharmaceutical opioid medications.
- Massachusetts: Acquisition of Hope Heal Health, Inc. (HHH) and an affiliated real estate entity with assets including state registration and licensing that will allow for cultivation, manufacturing, processing, and the establishment and operation of a medical marijuana dispensary, with the ability to obtain up to three medical marijuana dispensary licenses and three adult-use dispensary licenses.
- Arizona: Acquisition of Arizona Facilities Supply, LLC and certain of its subsidiaries, providing two cultivation facilities, one processing facility and one dispensary.
Awards and Recognition
- Co-Founder and CEO Charlie Bachtell was appointed to the cannabis subcommittee of Illinois Governor-elect JB Pritzker’s transition team. Bachtell is the only cannabis industry operator appointed to provide input that will shape the future of the cannabis program in Illinois.
- Cresco was named to the prestigious “Cannabis 100” list recognizing industry leaders and entrepreneurs by Green Entrepreneur, a division of Entrepreneur.com.
- Cresco was named among the best companies to work for in cannabis by MJ Magazine.
- Cresco was the first-ever cannabis company to win a national Healthcare Advertising Award.
- Cresco was also the first-ever cannabis company to receive a Summit International Award for creative, marketing and advertising.
A core principle of the company is to build a team of subject matter experts to propel Cresco’s growth in every vertical of the business. Recent hires include:
- Chief Experience Officer: Scott Wilson, former global creative director for Nike.
- Senior Vice President of Product Development and Commercialization: Todd West, former Lifeway Foods executive.
- Vice President of Consumer Experience: Cris Rivera, previously a senior director of marketing for MillerCoors.
- Vice President of Brand Marketing: Cory Rothschild, former director of consumer engagement for Gatorade, a PepsiCo company.
In addition to the above key hires, Cresco has recruited experts across every industry from companies including Stericycle, Abbvie, Abbott, Cushman & Wakefield, Pandora and BMO Financial Group.
Conference Call and Webcast
The company will hold a conference call and webcast to discuss its business and financial results next Monday, Dec.17, 2018 at 5 p.m. Eastern Time (4 p.m. Central Time). The conference call may be accessed via Cresco Labs’ investors website at investors.crescolabs.com or by dialing 866-688-4235 (409-216-0711 for international callers) and entering conference ID 5047018. Archived access to the webcast will be available for one year on Cresco's investors website.
Consolidated Financial Statements
The company’s unaudited consolidated interim financial statements and accompanying notes for the third quarter 2018 are available under the company's profile on SEDAR at www.sedar.com and on Cresco’s investors website at investors.crescolabs.com.